Latest / Pharmacy Podcast Network / Navigating the Digital Era and Beyond for Engaging Key Decision Makers in Specialty Pharmacy | NASP Specialty Pharmacy Podcast
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:08Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:26Speaker 2: You are listening to the NASP podcast. This Specialty Pharmacy
- 0:31Speaker 2: podcast is a collaboration with the National Association of Specialty
- 0:35Speaker 2: Pharmacy and the Pharmacy Podcast Network. The mission of the
- 0:38Speaker 2: National Association of Specialty Pharmacy is to improve specialty pharmacy
- 0:42Speaker 2: practice by promoting continuing professional education and certification of specialty
- 0:48Speaker 2: pharmacists while advocating for public policies that ensure patient access
- 0:52Speaker 2: to specialty medications. As the healthcare industry's leading podcasts dedicated
- 0:57Speaker 2: to the pharmacy profession, the Pharmacy Podcast Network is proud
- 1:01Speaker 2: to bring our listeners the NASP Podcast in collaboration with
- 1:05Speaker 2: the National Association of Specialty Pharmacy.
- 1:08Speaker 3: Hello, my name is Sheila Arqutt and I am the
- 1:10Speaker 3: President and CEO of the National Association of Specialty Pharmacy.
- 1:13Speaker 3: I am delighted to welcome to very special guests doctor
- 1:16Speaker 3: Bridget Kans Schroeder and Lori Fasio. Bridget Kans Schroeder, pharm
- 1:21Speaker 3: d MPa b COP is an Associate director within the
- 1:25Speaker 3: Medical Affairs, Strategy and Publications Team at Market Access and
- 1:30Speaker 3: Healthcare Consulting Heart of Sankora. In this role, she leads
- 1:34Speaker 3: a team focused on medical affairs initiatives including medical information dissemination,
- 1:40Speaker 3: planning and execution, strategic support, and content development. Additionally, she
- 1:46Speaker 3: collaborates on global health economics and outcomes research activities including
- 1:51Speaker 3: protocol development and review and provision of clinical contexts for
- 1:55Speaker 3: real world evidence generation activities, Health economics and outcomes research,
- 2:00Speaker 3: road mapping and content development of Academy of Managed Care,
- 2:04Speaker 3: Pharmacy formulary, dossier's Global Value, Dossier's Advisory Board, training slide decks,
- 2:11Speaker 3: and scientific publications. Before joining Sancora, Doctor Schroeder was a
- 2:15Speaker 3: clinical pharmacy specialist at the Marquee Cancer Center at the
- 2:19Speaker 3: University of Kentucky in Lexington. She serves as a medical
- 2:23Speaker 3: oncology clinical specialist in their ambulatory clinic and as a
- 2:27Speaker 3: preceptor to students, residents, and medical fellows. Her research and
- 2:31Speaker 3: publication interests focus on immunotherapy and checkpoint inhibition. Doctor Schroder
- 2:37Speaker 3: received her Doctor of Pharmacy and Master of Public Health
- 2:40Speaker 3: Administration degrees in twenty fourteen from the University of Kentucky.
- 2:45Speaker 3: She completed two years of residency at Vanderbilt University Medical
- 2:49Speaker 3: Center in Nashville, Tennessee. She has been a Board certified
- 2:53Speaker 3: oncology pharmacist since twenty seventeen. Lorie Fasio is Head Manufacture
- 2:58Speaker 3: Strategy at Formulary Decisions. Lourie leads their business development team
- 3:02Speaker 3: in developing and executing sales strategies and tactics to enhance
- 3:06Speaker 3: the Formulary Decisions business. She collaborates with manufacturer subscribers to
- 3:12Speaker 3: ensure Formulary Decisions meets and continues to evolve with their
- 3:16Speaker 3: payer engagement in data insights needs. Prior to the acquisition
- 3:20Speaker 3: of Formulary Decisions by Senkora, formerly a mare Source Bergen,
- 3:25Speaker 3: Laurie led the market access Technologies team, including the Customs
- 3:28Speaker 3: Software Solutions group, at DYE Maxium since two thousand. Her
- 3:33Speaker 3: experience began at a large health benefit consulting firm. She
- 3:37Speaker 3: subsequently joined a PBM where she helped employers and insurance
- 3:40Speaker 3: companies manage complex and diverse healthcare formulary issues. Laurie later
- 3:45Speaker 3: joined a large biopharmaceutical manufacturer where she spearheaded their strategies
- 3:50Speaker 3: to enhance the company's presence and image within the private sector.
- 3:54Speaker 3: She is a frequent speaker at payer and manufacturer conferences
- 3:57Speaker 3: and webinars. Her understanding of both the market access environment,
- 4:01Speaker 3: unmet needs of manufacturers and payers, and the application of
- 4:05Speaker 3: state of the art technologies ensures customers achieve their key
- 4:09Speaker 3: business objectives. Laurie is a graduate of Western University with
- 4:13Speaker 3: a Bachelor of Science in Mathematics and Statistics focused on
- 4:18Speaker 3: actuarial science. Rigid and Laurie, thanks so much for.
- 4:21Speaker 4: Joining me today. Thank you for having us.
- 4:24Speaker 3: So let's start with what are the key components of
- 4:27Speaker 3: an effective digital engagement strategy for biopharma companies in the
- 4:31Speaker 3: pharmaceutical industry and why is that important.
- 4:35Speaker 5: This means not having only a one point in time
- 4:38Speaker 5: engagement that might be tied around a significant milestone such
- 4:44Speaker 5: as product approval, but one that builds over time and
- 4:48Speaker 5: ensures that there's a continuum of communication digitally.
- 4:52Speaker 6: And when we think of a.
- 4:53Speaker 5: Strong digital engagement strategy, it really is one that gets
- 4:58Speaker 5: involved with healthcare decision maker customers early and often throughout
- 5:03Speaker 5: the commercialization process, so that you are ensuring that your
- 5:08Speaker 5: customers have the information they need to make informed formula
- 5:13Speaker 5: replacement decisions to ultimately get the right treatments to patients
- 5:17Speaker 5: in a timely manner.
- 5:18Speaker 6: And when I think of biopharma.
- 5:20Speaker 5: Companies and their timeline, it can really be broken down
- 5:24Speaker 5: into three main components pre approval, approval.
- 5:29Speaker 7: And launch.
- 5:29Speaker 6: I'll put those two together, and then post approval.
- 5:33Speaker 7: And our experience has shown that healthcare decision makers.
- 5:36Speaker 5: Need different information at each of these time periods, and
- 5:40Speaker 5: it's really important that biopharma companies are reaching them with
- 5:44Speaker 5: what they need when they need it.
- 5:46Speaker 4: In fact, as a.
- 5:47Speaker 5: Best practice, we share the importance of curating your audience
- 5:52Speaker 5: early so that a biopharma subscriber can sustain engagement and
- 5:56Speaker 5: keep healthcare decision makers informed throughout the products life cycle
- 6:01Speaker 5: by continuing to raise awareness of the latest and greatest information.
- 6:06Speaker 8: Yeah, Laurie, that's exactly it. And I think you know,
- 6:08Speaker 8: before we get much further, Laurie and I have also
- 6:11Speaker 8: been asked by our legal team to make sure that
- 6:14Speaker 8: our listeners know they should do their own research and
- 6:16Speaker 8: making decisions related to the content we're discussing today.
- 6:19Speaker 4: So I promise them i'd say that.
- 6:21Speaker 8: So now I have, and so building on that, I
- 6:24Speaker 8: want to go into a little more detail about what
- 6:26Speaker 8: Laurie was mentioning around that pre approval, approval and post
- 6:31Speaker 8: approval phases. And really that pre approval time period occurs
- 6:36Speaker 8: up to two years prior to launch, and what we
- 6:38Speaker 8: focus on during that time period is building engagement to
- 6:42Speaker 8: ensure that healthcare decision makers are aware of where to
- 6:46Speaker 8: go to obtain, you know, the latest information on the
- 6:48Speaker 8: product as well as in the disease state.
- 6:50Speaker 4: So we're really building a product story.
- 6:53Speaker 8: At that time, and this can include a wide variety
- 6:56Speaker 8: of topics like the patient journey, burden of illness, disease state.
- 7:00Speaker 8: But for the most part, our pre approval stage really
- 7:03Speaker 8: focuses on the unmet needs and highlighting that in a
- 7:06Speaker 8: population of interests.
- 7:07Speaker 4: And I want to call out for our listeners here
- 7:10Speaker 4: at NASP.
- 7:11Speaker 8: This could be as simple as explaining that a product
- 7:14Speaker 8: is an oral formulation and a biopharma company expects that
- 7:18Speaker 8: will be distributed through specialty pharmacy. So that's something that
- 7:21Speaker 8: would be really important to know and valuable to note
- 7:23Speaker 8: upfront for planning purposes.
- 7:27Speaker 4: And really then as we move into the product.
- 7:29Speaker 8: Approval phase, it's important for our healthcare decision makers to
- 7:32Speaker 8: receive support with different resources like payer value propositions, pri
- 7:37Speaker 8: authorization forms, formulary kits, all these resources that help communicate
- 7:41Speaker 8: that key product information to support actual formulary decision making
- 7:45Speaker 8: now that the product's approved and then of course in
- 7:48Speaker 8: the post approval stage, that support.
- 7:50Speaker 4: Needs to be continued.
- 7:52Speaker 8: So that could be in the form of additional value
- 7:54Speaker 8: demonstration like using health economics and outcomes research, which we
- 7:58Speaker 8: frequently refer to as AI you are. It could include
- 8:01Speaker 8: cost effectiveness models or retrospective database studies as well as
- 8:06Speaker 8: comparative effectiveness research.
- 8:09Speaker 5: Yeah, and I think the important point here is that
- 8:13Speaker 5: while the while the information varies over time, it's critical
- 8:16Speaker 5: that a biopharma company continue to communicate to that stakeholder audience,
- 8:21Speaker 5: particularly because as we know, therapeutic classes are continually being
- 8:25Speaker 5: re evaluated as new products enter the market pay place
- 8:29Speaker 5: and or existing products or seeking new indications. So coming
- 8:33Speaker 5: up with a digital engagement strategy that provides this thoughtful roadmap,
- 8:38Speaker 5: as bridget outlines, ensures that these professionals are receiving the
- 8:43Speaker 5: most current information even when biopharma companies may not be
- 8:46Speaker 5: connecting with them daily through live interactions.
- 8:51Speaker 3: So what are some examples of like a stakeholder audience
- 8:53Speaker 3: are we talking about, like payers or patients or prescribers?
- 8:56Speaker 7: Who are we talking about?
- 8:58Speaker 8: You nailed it, Sheila, talking about all the above, Okay,
- 9:03Speaker 8: And I think that's something that you'll hear Laurie and
- 9:05Speaker 8: I talk about throughout the podcast. Is digital engagement and
- 9:09Speaker 8: communication in general starts with understanding your audience. So as
- 9:13Speaker 8: Laurie gets more into formulary decisions and focusing on Sankhor's
- 9:17Speaker 8: digital platform, the main audience there is going to be payers,
- 9:22Speaker 8: but in general throughout the podcast as well, we'll also
- 9:25Speaker 8: be thinking about patients as well as healthcare providers, so
- 9:30Speaker 8: really encompassing a diverse group of audiences.
- 9:34Speaker 3: Okay, and I'm sure the messaging is quite different, right,
- 9:36Speaker 3: even the way the messaging is structured.
- 9:39Speaker 8: Absolutely, And you know, one of our big sort of
- 9:43Speaker 8: themes that we talk about is meeting the audience where
- 9:46Speaker 8: they are, and that that really comes into play, especially
- 9:50Speaker 8: in digital engagement, you know, finding our audiences, giving them
- 9:53Speaker 8: information where they want to receive it, when they want
- 9:56Speaker 8: to receive it, and in their preferred format.
- 9:58Speaker 4: Oh exactly right.
- 9:59Speaker 3: There's so much competing for their attention, right if it
- 10:01Speaker 3: doesn't immediately resonate, they're onto something else great, So how
- 10:06Speaker 3: can biopharma companies leverage data analytics to enhance their digital
- 10:11Speaker 3: engagement efforts with healthcare providers.
- 10:14Speaker 5: I think what's really important here is that it's in
- 10:18Speaker 5: the best interest of these biopharma companies to understand if
- 10:21Speaker 5: and how their content is being engaged with, since there's
- 10:25Speaker 5: a lot of time and money that's invested into the
- 10:27Speaker 5: development of these customer facing pieces. And when I think
- 10:31Speaker 5: of the Formula Decisions platforms specifically, we're targeted on, as
- 10:36Speaker 5: Bridget mentioned earlier, the payers, your traditional payers, your health plans,
- 10:40Speaker 5: your PBMs, but we also have hospitals, IDNs, health systems,
- 10:44Speaker 5: public health systems who are using this platform and so
- 10:49Speaker 5: having access to data analytics such as what types of
- 10:53Speaker 5: content have the most activity, or which of these organization
- 10:57Speaker 5: types are accessing the pieces of content they're posting, just
- 11:01Speaker 5: to name a few, helps a biopharma company better understand
- 11:05Speaker 5: what's important and how it might vary depending on the
- 11:08Speaker 5: stakeholder audiences. As we mentioned earlier, so for instance, Formula
- 11:13Speaker 5: Decisions captures this data to determine the engagement.
- 11:16Speaker 7: Level of each of those resources that has been.
- 11:18Speaker 5: Shared as posted bier subscribers to the platform. And I
- 11:22Speaker 5: think what's really interesting is an analysis that we recently
- 11:26Speaker 5: did where we looked at everything that biopharma companies have
- 11:31Speaker 5: posted in their curated repositories that they have available to
- 11:34Speaker 5: them as a subscriber on the platform where they can
- 11:37Speaker 5: post as much content as varied content as they want
- 11:41Speaker 5: over time, obviously subject to their internal review and approval process.
- 11:46Speaker 5: But when we looked at that, what was interesting to
- 11:49Speaker 5: note was that what was being access most frequently wasn't
- 11:54Speaker 5: necessarily what was being posted most frequently. So product information,
- 12:00Speaker 5: for example, which I recognize as a broad category that
- 12:03Speaker 5: could include anything from pre approval information exchange decks to
- 12:08Speaker 5: known as PI, to billing encoding, guides or pricing overviews
- 12:12Speaker 5: and more. To help economics and Outcroom's research and real
- 12:16Speaker 5: world evidence, those had the highest activity by our community
- 12:20Speaker 5: of healthcare decision makers. Yet clinical trial publications were the
- 12:24Speaker 5: most consistently posted resource by our biopharma companies. So you
- 12:32Speaker 5: look at that and you simply can't get that information
- 12:35Speaker 5: when you send out a file to a customer, right
- 12:38Speaker 5: You're not going to understand how.
- 12:39Speaker 6: That's being used.
- 12:40Speaker 5: If it's being used where they're going, what they're looking at,
- 12:43Speaker 5: how much time they're spending. And I think the analytics
- 12:46Speaker 5: really shouldn't just stop at a high level. That should
- 12:49Speaker 5: be further broken down by stage, which is what we
- 12:52Speaker 5: discussed earliers that you know, in pre approval, at launch,
- 12:56Speaker 5: post approval, what are they looking at, what are they
- 13:00Speaker 5: gravitating to because we know that changes over time. And
- 13:04Speaker 5: then I think to round that out, you want to
- 13:06Speaker 5: get feedback on the product or on the information that
- 13:10Speaker 5: you're posting, so that can ensure that you're reaching your
- 13:14Speaker 5: customers where they are with the information they need when
- 13:17Speaker 5: they need it. So the goal really should be to
- 13:20Speaker 5: obtain the most comprehensive understanding through both activity metrics and
- 13:26Speaker 5: insights via feedback. And that's the power of data analytics
- 13:30Speaker 5: and should really be table stakes for any digital engagement strategy.
- 13:36Speaker 4: Yeah, and I think you know, what you're saying.
- 13:38Speaker 8: Is so important, Lri because our current market, the resources
- 13:42Speaker 8: are continuously constrained, right, Like, I think we're all facing
- 13:45Speaker 8: that no matter what part of the industry you're in,
- 13:48Speaker 8: and it's really.
- 13:49Speaker 4: Important that we then take those data analytics and use them.
- 13:53Speaker 8: So you know, Lourie is talking about how we can
- 13:57Speaker 8: get these analytics from things we've done in the past,
- 14:00Speaker 8: and then what I think about next is how does
- 14:02Speaker 8: that inform the future? So those data analytics can really
- 14:05Speaker 8: be brought into our biopharma company clients and inform their
- 14:09Speaker 8: strategic development, help to prioritize where.
- 14:12Speaker 4: They're going to put their resources.
- 14:15Speaker 8: You focusing on what kind of engagement their materials are having,
- 14:19Speaker 8: when to develop those and how to post them and
- 14:22Speaker 8: where to share them.
- 14:23Speaker 3: And when we're talking about pre approval, that nothing pre
- 14:26Speaker 3: approval goes to patients. Is that correct?
- 14:28Speaker 8: Yes, in the sense that pre approval information exchange is
- 14:33Speaker 8: a very highly regulated communication piece, so that is strictly
- 14:40Speaker 8: for payers. It's not focused on patients, So that's correct.
- 14:44Speaker 8: That doesn't mean that patients don't get some type of
- 14:47Speaker 8: information about products. Of course, clinicaltrials dot gov, publicly available
- 14:53Speaker 8: trial results, things of that nature are certainly available.
- 14:57Speaker 4: But when we talk about.
- 14:58Speaker 8: Biopharma customers specifically engaging with PIE, that is to the
- 15:02Speaker 8: pay audience, Okay, And I think.
- 15:05Speaker 5: That's the really nice thing when I think of our platform,
- 15:08Speaker 5: is that our audience is an audience that is approved
- 15:13Speaker 5: in terms of the criteria that they meet. They are
- 15:15Speaker 5: an approved audience to receive pre approval information.
- 15:20Speaker 3: Yeah, that's awesome. In what ways can digital engagement improve
- 15:24Speaker 3: communication and collaboration between biopharma companies and their stakeholders?
- 15:30Speaker 4: Yeah, I can take this one, Shila.
- 15:32Speaker 8: So you know, digital engagement has really evolved to become
- 15:35Speaker 8: bi directional, and that fosters a much more collaborative environment,
- 15:38Speaker 8: specifically for us between our biopharma companies and their stakeholders
- 15:43Speaker 8: like the payer audience. And like I mentioned earlier that
- 15:46Speaker 8: one key thing that we emphasize and really talk about
- 15:49Speaker 8: continuously and effective communication.
- 15:51Speaker 4: Is meeting our audience where they're at.
- 15:53Speaker 8: And I think we can all appreciate that we spend
- 15:56Speaker 8: far too much time online right as this normal people
- 15:58Speaker 8: in our day to day and I think we forget
- 16:01Speaker 8: that so do our healthcare decision makers because at the
- 16:04Speaker 8: end of the day, they're also just normal people. So
- 16:07Speaker 8: what we've consistently heard over time is they really want
- 16:10Speaker 8: information that's easy to access and it's early in the
- 16:13Speaker 8: product life cycle. On the other side of the fence,
- 16:16Speaker 8: then our biopharma partners really want to be efficient and
- 16:20Speaker 8: they want to be effective with their content development, so
- 16:22Speaker 8: it's important to them to understand what kind of information
- 16:26Speaker 8: is valuable, which gets back to that data analytics and
- 16:29Speaker 8: when that information is valuable. But it's also equally important
- 16:33Speaker 8: to understand how a healthcare decision maker prefers to receive that.
- 16:36Speaker 4: Information so that biopharma can make a plan.
- 16:40Speaker 8: I think we've alluded to it a little bit here,
- 16:42Speaker 8: But there's compliance and there's regulation to consider in the
- 16:45Speaker 8: background of making sure that we're digitally engaging compliantly and
- 16:50Speaker 8: following regulations. So I think that that digital engagement and
- 16:55Speaker 8: having that bi directional feedback is a really great path
- 16:58Speaker 8: that we're going down.
- 17:00Speaker 5: And I think that's a good point Bridget because by
- 17:03Speaker 5: now biopharma companies certainly should recognize that they need to
- 17:07Speaker 5: leverage various channels to meet their stakeholder customers, and digital
- 17:12Speaker 5: plays a vital role in that process, but it's not
- 17:14Speaker 5: the only role, and a best practice really is to
- 17:17Speaker 5: have a strong coordination of effort between the feet on
- 17:22Speaker 5: the street, their field teams who are going out and
- 17:24Speaker 5: talking to their pay our customers, and digital engagement, and
- 17:28Speaker 5: then to really leverage those advanced analytics.
- 17:32Speaker 6: That they receive back through that.
- 17:34Speaker 5: Digital engagement to facilitate field at team activation, and what
- 17:38Speaker 5: I mean by that is recognizing where their stakeholder customers
- 17:43Speaker 5: are engaging with content, but also equally where they may
- 17:46Speaker 5: not be engaging with content, and where there's an opportunity
- 17:50Speaker 5: for the field team to come in and really educate them.
- 17:53Speaker 5: So when I look at that, I think it goes
- 17:56Speaker 5: a long way in terms of partnership between biopharma company
- 18:00Speaker 5: these and their customer stakeholders when they receive the feedback
- 18:04Speaker 5: that I mentioned earlier and then they act upon it
- 18:06Speaker 5: to provide what their customers are looking for.
- 18:09Speaker 6: Yeah, absolutely, Laurie.
- 18:11Speaker 8: I think one thing that we are more commonly recommending
- 18:14Speaker 8: is to have these biopharma companies develop a database of
- 18:17Speaker 8: content right that can be available for use, tagged to
- 18:22Speaker 8: specific audiences, with specific audience messaging, again compliant in line
- 18:26Speaker 8: with regulations, and then they can use that database and
- 18:30Speaker 8: update it intentionally to meet the needs of healthcare decision makers.
- 18:33Speaker 8: And I think this is a shift that we've seen
- 18:36Speaker 8: in the industry over time, versus making one off pieces
- 18:40Speaker 8: for a specific audience, really moving to develop that repository
- 18:44Speaker 8: of information that can then be tweaked and changed to
- 18:48Speaker 8: meet your audience needs.
- 18:50Speaker 4: And I think kind of along those same lines.
- 18:52Speaker 8: It's really important that companies create internal standard operating procedures,
- 18:57Speaker 8: and these can help provide guidance and really increase the
- 18:59Speaker 8: comfort with sharing what's traditionally you know, live content into
- 19:04Speaker 8: digital content and really making sure that this is consistent
- 19:08Speaker 8: and compliant. And this is going to help all of
- 19:10Speaker 8: the content creators, you know, so that at each company
- 19:13Speaker 8: they're not asking the same questions every time they're developing
- 19:16Speaker 8: and sharing materials, and everyone along the continuum feels just
- 19:19Speaker 8: a little bit more comfortable with digital engagement.
- 19:22Speaker 3: So what role do online platforms play in shaping the
- 19:25Speaker 3: perception of a manufacturer among healthcare professionals?
- 19:30Speaker 5: So I think it's an interesting question because we're now
- 19:34Speaker 5: talking beyond product but to the manufacture themselves, and we
- 19:38Speaker 5: think of the pandemic, and obviously in the pandemic, we
- 19:41Speaker 5: saw a significant shift in terms of all of us
- 19:45Speaker 5: and healthcare decision makers included leveraging online resources and for
- 19:50Speaker 5: this stakeholder audience, they were using that as a way
- 19:53Speaker 5: to access the information they needed when in person simply
- 19:57Speaker 5: was not possible. And then post pandemic, as those of
- 20:01Speaker 5: us who work remotely certainly can appreciate, most organizations have
- 20:05Speaker 5: shifted from a primarily in person work environment to one
- 20:08Speaker 5: that's hybrid or remote. And when we think about that,
- 20:11Speaker 5: we think about the perception of the manufacturer and meeting
- 20:15Speaker 5: them where their customers, where they're at. We think of
- 20:19Speaker 5: what the field team is doing and the feedback that
- 20:22Speaker 5: they're getting through those live engagements, and then leveraging an
- 20:27Speaker 5: online platform to validate what that field team is hearing
- 20:31Speaker 5: and in many cases, as subscribers have told me, they
- 20:35Speaker 5: use that to monitor the perception of them as a
- 20:38Speaker 5: manufacturer overall. In terms of that partnership, one of the
- 20:43Speaker 5: other things that we think about is that a significant
- 20:47Speaker 5: time reviewing digital resources in comparison to non digital ones
- 20:53Speaker 5: has come out as a consistent theme, and there was
- 20:56Speaker 5: external research that was done that showed that eighty percent
- 20:59Speaker 5: of help care decision makers prefer to access information digitally.
- 21:03Speaker 6: So it's important for biofarmer companies.
- 21:05Speaker 7: As a partner to have a footprint in that channel
- 21:09Speaker 7: as well.
- 21:10Speaker 8: And I want to jump in on that LORI because
- 21:12Speaker 8: I do think that that data is so important and
- 21:16Speaker 8: building on that. Eighty seven percent of decision makers also
- 21:20Speaker 8: said that they prefer either a combination of traditional and
- 21:23Speaker 8: digital communication channels or for there to be more in
- 21:26Speaker 8: person meetings. So we're hearing both, right, Like our healthcare
- 21:30Speaker 8: decision makers want to be able to access that information digitally,
- 21:34Speaker 8: but they don't want to lose the human touch. And
- 21:36Speaker 8: I think that's really key for you know, our manufacturer,
- 21:40Speaker 8: our biopharma partners to hear because it's still really important
- 21:43Speaker 8: that they're engaging with these stakeholders in a variety of ways.
- 21:47Speaker 8: And I think what that means is our biopharma partners
- 21:51Speaker 8: have to have effective engagement in a multi channel approach.
- 21:55Speaker 8: So it allows those decision makers to have the flexibility
- 21:59Speaker 8: in how they consume it information where and when it's most.
- 22:02Speaker 4: Applicable for them.
- 22:03Speaker 8: And I think digital platforms, like you said, Laurie, can
- 22:06Speaker 8: really serve as that compliment to in person engagement. It
- 22:09Speaker 8: allows the decision makers to go back and revisit content.
- 22:12Speaker 8: You know, they've got it at their fingertips. They don't
- 22:14Speaker 8: have to reach out, but they still have you know,
- 22:17Speaker 8: contacts at our biopharma companies and they still have relationships.
- 22:21Speaker 4: And I think that this really.
- 22:22Speaker 8: Shows that the perception of a manufacturer is important and
- 22:27Speaker 8: that manufacturers are willing to evolve with the times, right,
- 22:30Speaker 8: Like they're trying to do research to understand what their
- 22:34Speaker 8: audiences want and what information they need, and I think
- 22:37Speaker 8: they're really willing to try new things, and I think
- 22:39Speaker 8: all of those things resonate with our decision makers and
- 22:42Speaker 8: impact the perception of the biopharma customer.
- 22:46Speaker 6: Yeah, And I think that's why it's.
- 22:47Speaker 5: Important to have that coordination right between doing live and
- 22:52Speaker 5: doing digitally and ensure that they're sharing the insights more
- 22:55Speaker 5: broadly across the organization.
- 22:57Speaker 7: So that they can continue to enhance that partnership.
- 23:00Speaker 4: Absolutely.
- 23:01Speaker 8: I think one of the buzzwords I really appreciate right
- 23:03Speaker 8: now is a surround sound approach, so making right, it's
- 23:07Speaker 8: kind of cool, making sure, and that's what we're hearing.
- 23:10Speaker 8: The decision makers want things in a variety of ways.
- 23:14Speaker 8: So we've talked a lot about formulary Decisions, which is
- 23:17Speaker 8: Sinkora's digital platform, and that's more of a closed system,
- 23:21Speaker 8: so our users are validated to again make sure that
- 23:24Speaker 8: that audience is following regulations and we're communicating in a
- 23:28Speaker 8: compliant way that our manufacturers don't have to worry about
- 23:31Speaker 8: as much.
- 23:32Speaker 4: But there are other.
- 23:34Speaker 8: Platforms, right, Like we think about social media platforms that
- 23:37Speaker 8: are more professional doximity LinkedIn These can really also be
- 23:41Speaker 8: used to share information or entice healthcare decision makers to
- 23:45Speaker 8: either reach out directly to the biopharma company for those
- 23:49Speaker 8: more traditional in person engagements, or on the flip side,
- 23:53Speaker 8: to be more engaged with formulary decisions. And even more so,
- 23:57Speaker 8: when we're thinking about more of these open systems, it's
- 24:00Speaker 8: really important to have internal alignment on the logistics of
- 24:03Speaker 8: how you use these systems and the logistics of the
- 24:06Speaker 8: posts and consider different options. So, for example, a lot
- 24:11Speaker 8: of our biopharma companies struggle with like are we going
- 24:14Speaker 8: to allow comments on social media posts? Because that opens
- 24:18Speaker 8: a can of worms of potential information that they have
- 24:21Speaker 8: to monitor and they have to respond to.
- 24:24Speaker 4: So that's important to consider.
- 24:25Speaker 8: And then on the flip side, if you are putting
- 24:28Speaker 8: this effort and time and resource into using these other platforms,
- 24:32Speaker 8: you have to have some way to measure success. So
- 24:34Speaker 8: thinking about you know, what type of performance indicators are
- 24:37Speaker 8: you going to monitor and use to determine what engagement
- 24:40Speaker 8: that post has generated?
- 24:43Speaker 6: Yeah.
- 24:43Speaker 9: Absolutely, and online platforms such as ours of formula Decisions,
- 24:48Speaker 9: which is bridget mentioned is a closed platform only for
- 24:52Speaker 9: validated healthcare decision makers offers this flexibility and then can
- 24:57Speaker 9: serve as this consolidated portal where healthcare professionals.
- 25:01Speaker 5: Can conveniently access resources from a wide variety of biopharma
- 25:05Speaker 5: companies and products as well as third party sources, as
- 25:10Speaker 5: opposed to having to navigate to multiple resources. And I
- 25:14Speaker 5: recognize that biopharma companies also find value in having their
- 25:17Speaker 5: own pair portals, and I definitely support that. I think
- 25:22Speaker 5: thinking of multiple channels having formulary decisions is another one
- 25:28Speaker 5: to consider, because we already know that healthcare decision makers
- 25:31Speaker 5: are coming here as a trusted third party source. And plus,
- 25:35Speaker 5: as Bridget mentioned earlier, we verify that they meet the
- 25:39Speaker 5: FDA definition of a pay or when they register and
- 25:42Speaker 5: certainly before they have access to the platform, and then
- 25:45Speaker 5: we ensure that they reactivate their access every six months.
- 25:49Speaker 5: And this gives confidence to our biopharma company subscribers that
- 25:54Speaker 5: they can share information in this platform and know it's
- 25:58Speaker 5: reaching the audience that meets the compliance needs. And then
- 26:02Speaker 5: feedback from our community, our healthcare decision maker community has
- 26:05Speaker 5: generally been favorable, with many recognizing that the platform's comprehensive
- 26:10Speaker 5: approach to information sharing creates a multifaceted approach for them
- 26:18Speaker 5: to have so many resources available, and I think pharma
- 26:21Speaker 5: companies recognize that their participation in this closed, secure platform
- 26:26Speaker 5: demonstrates partnership which goes a long way with their customers
- 26:29Speaker 5: and a willingness to meet them.
- 26:30Speaker 4: Where they are.
- 26:32Speaker 8: Absolutely, I think that really ties it back to Sheila's question, right, like,
- 26:36Speaker 8: by participating in digital engagements, I think biopharma companies in
- 26:41Speaker 8: general are saying they understand, you know, healthcare decision makers
- 26:44Speaker 8: are really busy. They have a lot of demands for
- 26:46Speaker 8: their time, and they want to evolve. They want to
- 26:49Speaker 8: provide the data that these decision makers need in an
- 26:52Speaker 8: easily accessible format, and they want to make sure that
- 26:55Speaker 8: they have their information so they can conduct product reviews
- 26:58Speaker 8: to talk about reimburse and make sure that those contracting
- 27:02Speaker 8: decisions are done in as time efficient a manner as possible.
- 27:07Speaker 3: So do you think did COVID Is this a result
- 27:11Speaker 3: of COVID? Did COVID accelerate right? This, I guess need
- 27:16Speaker 3: an acceptance of digital engagement.
- 27:19Speaker 5: Well, when I think back to when we launched Formulary
- 27:22Speaker 5: Decisions in twenty ten, there was a recognition on the
- 27:27Speaker 5: part of the Academy of Managed Care Pharmacy that the
- 27:30Speaker 5: old way of doing things sharing a dossier by sending
- 27:33Speaker 5: out a binder just really.
- 27:35Speaker 7: Wasn't the way anymore, and so I.
- 27:39Speaker 5: Think that started a change in terms of how to
- 27:43Speaker 5: share information.
- 27:45Speaker 7: We've seen an increase engagement over time.
- 27:48Speaker 10: I will say it did get it was accelerated as
- 27:51Speaker 10: a result of COVID, But interestingly enough, when we look
- 27:55Speaker 10: at just the last five years, so going up to
- 27:59Speaker 10: ending in twenty twenty three, I think we saw an
- 28:01Speaker 10: eight fold increase in engagement and that just continues to grow.
- 28:06Speaker 6: So I do agree with you.
- 28:07Speaker 5: I think I think COVID played a role, but I
- 28:10Speaker 5: think it was more about accelerating this as opposed to
- 28:13Speaker 5: something that was started and everyone was recognizing there was
- 28:17Speaker 5: a need for it and.
- 28:19Speaker 7: We're only going to continue to evolve with one percent.
- 28:24Speaker 8: And I think when we then considered those additional audiences
- 28:27Speaker 8: like our healthcare providers that are seeing patients every day
- 28:31Speaker 8: and patients themselves, I think COVID definitely accelerated like their need.
- 28:36Speaker 4: For digital engagement, right, you know, we've.
- 28:38Speaker 8: Got these sort of exaggerated social platforms now like TikTok
- 28:43Speaker 8: where honestly, doctors are talking to patients on TikTok. My lord,
- 28:49Speaker 8: I know, I know, but it's really cool, like it
- 28:52Speaker 8: provides this just absolutely untapped educational potential. And I think
- 28:57Speaker 8: what COVID did was make some biofarm companies really have
- 29:01Speaker 8: that reckoning. I think, as Laurie said, communicating with payers
- 29:06Speaker 8: in a digital way.
- 29:07Speaker 4: Has been coming for a long time.
- 29:09Speaker 8: I think where biopharma companies have been able to draw
- 29:12Speaker 8: the line is commuting communicating digitally with providers and patients
- 29:16Speaker 8: because they just lose so much control of the communication
- 29:19Speaker 8: platform and of the resource. But COVID really forced that
- 29:24Speaker 8: conversation to come back to the forefront.
- 29:26Speaker 4: And I think we're seeing companies.
- 29:28Speaker 8: Develop standard operating procedures to participate because they just understand
- 29:33Speaker 8: that there's such an opportunity to put out, you know,
- 29:36Speaker 8: unbranded disease state education. You know, it does not have
- 29:40Speaker 8: to be products specific. At the end of the day,
- 29:42Speaker 8: we are all patient centric and we're trying to create
- 29:45Speaker 8: a better healthcare space, and I think that there's so
- 29:47Speaker 8: many opportunities now. So I do think COVID allowed biopharma
- 29:51Speaker 8: companies to reprioritize that, and I think in my world,
- 29:56Speaker 8: in the metafare space, we're seeing it in the form
- 29:59Speaker 8: of digital opinion leaders. Where we used to really only
- 30:02Speaker 8: focus on key opinion leaders, which were providers that were
- 30:05Speaker 8: influencing a disease space or influencing treatment guidelines, and now
- 30:09Speaker 8: we've got to also consider digital opinion leaders. So what
- 30:12Speaker 8: are these TikTok docs talking to patients about? And you
- 30:16Speaker 8: know who's following them?
- 30:18Speaker 4: Healthcare providers patients.
- 30:19Speaker 8: There's just such a diversity out there, and I think
- 30:22Speaker 8: COVID's allowing us to bring that back to the forefront.
- 30:26Speaker 3: Sure, yeah, and I think the push to go green right,
- 30:28Speaker 3: like probably when you know formulary decisions are in twenty
- 30:32Speaker 3: ten when it went live, right, and I remember like
- 30:35Speaker 3: the dotsier's and then I remember like the P and
- 30:37Speaker 3: T packets as well, and then I've heard, you know,
- 30:39Speaker 3: Covid that all went digital as well. But I remember
- 30:42Speaker 3: lugging that around and you know, printing thirty copies of
- 30:45Speaker 3: that and so so yeah, I think, you know, COVID
- 30:49Speaker 3: was the the accelerator of that, which is a good thing, right,
- 30:52Speaker 3: we don't you know, So, how can biopharma companies ensure
- 30:56Speaker 3: that their digital engagement strategies comply with us all the
- 31:00Speaker 3: industry regulations and guidelines.
- 31:03Speaker 5: Well, we know that digital slot solutions provide this really
- 31:09Speaker 5: unique opportunity for rapid, essentially real time sharing of resources and.
- 31:14Speaker 6: Generation of insights.
- 31:16Speaker 11: And due to the fast moving nature of this process,
- 31:20Speaker 11: biofarm companies really need to ensure that their practices still
- 31:23Speaker 11: fall in line with the FDA guidance, particularly when thinking
- 31:27Speaker 11: about what is appropriate to convey during pre approval, because
- 31:30Speaker 11: it is very strict and focused, and.
- 31:34Speaker 5: It's important when we speak of pre approval.
- 31:37Speaker 7: In addition to what they are sharing, to ensure.
- 31:40Speaker 5: That they have a communication mechanism in place to connect
- 31:45Speaker 5: with those healthcare decision makers who have accessed earlier content
- 31:50Speaker 5: with updated information once it becomes available, because that is
- 31:53Speaker 5: a requirement as well.
- 31:56Speaker 8: Yeah, and I think you know what's really important here
- 31:59Speaker 8: when we talk about digital engagement and digital resources, it's
- 32:03Speaker 8: that it's not different, right, So we really need to
- 32:06Speaker 8: intentionally track these resources just as you would track engaging
- 32:10Speaker 8: face to face with a healthcare decision maker or other audience,
- 32:13Speaker 8: and making sure that we're following all of the guidance
- 32:16Speaker 8: that applies there. So, reporting adverse events in a timely manner.
- 32:19Speaker 8: You know, if product quality issues are reported, making sure
- 32:23Speaker 8: that those are reported in a timely manner as well.
- 32:26Speaker 8: So that's what's scared you know, biopharma companies away in
- 32:30Speaker 8: the past because it does take some time and investment upfront.
- 32:34Speaker 4: To ensure you're setup for success.
- 32:35Speaker 8: But again, with a little bit of effort, a little
- 32:37Speaker 8: bit of standard operating procedures dropped in there, digital engagement
- 32:41Speaker 8: can be done efficiently and compliantly. So I think an
- 32:45Speaker 8: example would be that like making sure information communicated is
- 32:50Speaker 8: scientifically sound and presented within the correct context. So you know,
- 32:54Speaker 8: if you're presenting the prevalence of a disease state you
- 32:57Speaker 8: need to present you know how that estimated or how
- 33:01Speaker 8: the incidence of an adverse event was derived within an
- 33:03Speaker 8: economic model. So making sure that those steps that you
- 33:06Speaker 8: would take when you're presenting these resources live, you're taking
- 33:10Speaker 8: those steps just a slightly different manner when you're doing
- 33:13Speaker 8: these things digitally. And I think ultimately our biofarmer companies
- 33:16Speaker 8: should exercise oversight right again, work construction, standard operating procedures,
- 33:21Speaker 8: anything that they would have had in place for other
- 33:24Speaker 8: communication venues, do it for your digital engagement and that
- 33:27Speaker 8: will make sure that your digital strategies are intentionally compliant,
- 33:31Speaker 8: just like any of your other communication strategies.
- 33:36Speaker 3: So what are some innovative tools or technologies that biopharma
- 33:39Speaker 3: companies can use to enhance their digital engagement. There's so
- 33:43Speaker 3: much right happening with technology and AI, and you know,
- 33:47Speaker 3: what are some of these tools and technologies they should consider?
- 33:51Speaker 7: AI was exactly where I was going, Shila.
- 33:54Speaker 5: You know, when we look towards the future and AI
- 33:58Speaker 5: emerges as a key player, and we all hear about
- 34:01Speaker 5: AI and how it's being used in many different ways,
- 34:03Speaker 5: good and bad, both for personal and professional purposes. And
- 34:08Speaker 5: when I think of us, and specifically the Formulary Decisions platform,
- 34:13Speaker 5: we're exploring how we can compliantly integrate AI into our
- 34:17Speaker 5: platform and this would help to facilitate meaningful interactions between
- 34:21Speaker 5: both our users who are healthcare decision makers and a
- 34:25Speaker 5: biofarmer company subscribers.
- 34:27Speaker 4: So what does that mean?
- 34:29Speaker 7: I don't think we really know yet what role AI
- 34:31Speaker 7: might be.
- 34:32Speaker 5: Incorporated to our platform, right, We haven't fully thought that through.
- 34:37Speaker 5: It could be as simple as and I say simple
- 34:39Speaker 5: because I'm not the one developing it. It could be
- 34:41Speaker 5: as simple as benefiting our users to help them synthesize
- 34:45Speaker 5: all of the information that's available to them.
- 34:47Speaker 7: Both what they can collect publicly and is available.
- 34:51Speaker 5: To them within the platform and biopharma curated content that
- 34:55Speaker 5: they can only get through the platform or directly through
- 34:59Speaker 5: the a manufacturer themselves without them needing to pull all
- 35:04Speaker 5: of that information together themselves. Said another way, we hope
- 35:08Speaker 5: to be the AI that healthcare decision makers are using.
- 35:12Speaker 6: And when I think on the flip side and I
- 35:14Speaker 6: think of our.
- 35:14Speaker 5: Bio pharma company subscribers, AI might be leveraged in a
- 35:18Speaker 5: way to weave those activity metrics and feedback together to
- 35:22Speaker 5: quickly identify trends or consistent themes that they may need
- 35:26Speaker 5: to address so that it can be done more real time.
- 35:29Speaker 6: The beauty of AI is that it can pull so much.
- 35:31Speaker 5: Information together so that individuals can digest it faster. But
- 35:37Speaker 5: we don't know yet if, how, or when it will
- 35:40Speaker 5: be incorporated, but I will say that we do know
- 35:43Speaker 5: we will do so thoughtfully and with compliance in mind,
- 35:46Speaker 5: as it always is.
- 35:48Speaker 8: Yeah, absolutely, and I think you know, thinking about those
- 35:51Speaker 8: innovative tools and technology. The other thing that comes to
- 35:54Speaker 8: mind for me in the Metaphair's world is omnichannel engagement.
- 35:58Speaker 8: So omnichannel engaged was a buzzword from a couple of
- 36:02Speaker 8: years back now, but it's really meant to be again
- 36:05Speaker 8: a central repository of resources that can easily be tweaked
- 36:10Speaker 8: or easily be flexed to meet the needs of different customers,
- 36:14Speaker 8: different audiences. And then also there's meant to be a
- 36:18Speaker 8: digital component that brings insights back to make sure that
- 36:21Speaker 8: those pieces can be updated or make sure that performance
- 36:25Speaker 8: indicators are captured. And I think that we really haven't
- 36:29Speaker 8: realized that dream yet of omnichannel engagement, and I think
- 36:33Speaker 8: that's sort of the next frontier for the technology, and
- 36:37Speaker 8: maybe AI will help us move towards that true omnichannel
- 36:40Speaker 8: engagement as well.
- 36:44Speaker 3: So what challenges do biopharma companies face when they're implementing
- 36:47Speaker 3: digital engagement strategies and then how do they overcome them?
- 36:51Speaker 12: Thank you think the biggest challenge that I've heard as
- 36:54Speaker 12: our subscribers want to leverage formula decisions specifically, is how
- 37:01Speaker 12: to leverage digital engagement for both the communication of medical
- 37:05Speaker 12: information so that traditional requires an unsolicit request reactive response
- 37:12Speaker 12: to a.
- 37:13Speaker 5: Request from one of their customer stakeholders and more of
- 37:17Speaker 5: that promotional marketing information to the same healthcare decision maker
- 37:22Speaker 5: customers in a way that compliantly separates them both. So
- 37:27Speaker 5: when I think back to the evolution of this platform
- 37:29Speaker 5: and the things we've put in place they need, we
- 37:33Speaker 5: recognize that we've kept that separation, and we've gone so
- 37:37Speaker 5: far as not only to separate the content, but even
- 37:41Speaker 5: the metrics and feedback can be separated based on the
- 37:44Speaker 5: role of the user at the biopharma company.
- 37:47Speaker 6: And when pharma companies.
- 37:49Speaker 5: Are thinking of creating their own pair portals, I think
- 37:51Speaker 5: they need to keep this in mind as well to
- 37:54Speaker 5: better understand who's eligible to receive that specific piece of
- 37:58Speaker 5: information that they want to share.
- 38:02Speaker 8: And I think from my side, the biggest challenge we've
- 38:04Speaker 8: touched on it a few times, it's really, you know,
- 38:08Speaker 8: the fear of digital engagement and what that means for
- 38:10Speaker 8: compliance and what that means for their risk level, and
- 38:15Speaker 8: how can our biopharma customers get these tools and resources
- 38:18Speaker 8: internally approved with buy in from their legal, medical, regulatory,
- 38:23Speaker 8: promotional committees.
- 38:25Speaker 4: And I think what we've.
- 38:26Speaker 8: Seen work in the past is really just having an
- 38:28Speaker 8: open dialogue. So talk to your teams talk internally about
- 38:32Speaker 8: the risks of digital engagement.
- 38:34Speaker 4: And then the mitigation.
- 38:35Speaker 8: So certainly, just like with any other type of engagement,
- 38:38Speaker 8: there's different levels of risk, and if you have that
- 38:40Speaker 8: open dialogue internally, you know your company can really come
- 38:44Speaker 8: to a consensus about what risk they're comfortable with and
- 38:48Speaker 8: what mitigation strategies they're comfortable with, and then again write
- 38:51Speaker 8: it down, have that standard procedure so that people don't
- 38:55Speaker 8: have to guess, right, make sure that everyone within your
- 38:58Speaker 8: company is aligned on the executution of digital engagement in
- 39:01Speaker 8: how to decrease the risk, and that way, if you
- 39:05Speaker 8: can capture components that help, you know, report those adverse events,
- 39:09Speaker 8: report quality issues, make sure you're responding to unsolicited requests
- 39:12Speaker 8: for information, so really helping to engage there.
- 39:16Speaker 7: Yeah, that's a really important bridge point.
- 39:18Speaker 5: Bridget because something that the platform certainly takes into consideration
- 39:23Speaker 5: is this whole notion of reporting AES. And when healthcare
- 39:28Speaker 5: decision makers register for the platform, part of that registration
- 39:32Speaker 5: process includes agreeing to our general terms of use, and
- 39:36Speaker 5: in order to complete their registration, this includes acknowledging that this.
- 39:40Speaker 7: Is not where they should be reporting AES.
- 39:43Speaker 5: In fact, we include a link to where they could
- 39:45Speaker 5: report AES. And then this is reinforced again when these
- 39:49Speaker 5: healthcare decision makers want to complete any surveys available to
- 39:52Speaker 5: them to help mitigate those risks for biopharma companies.
- 39:58Speaker 3: So what best practices can BUIO from our companies adapt
- 40:01Speaker 3: to ensure that their digital engagement efforts resonate right with
- 40:04Speaker 3: a diverse hcdms to optimize market access.
- 40:10Speaker 6: When I think.
- 40:11Speaker 7: About this, I think of it really as a four
- 40:13Speaker 7: stage approach.
- 40:14Speaker 5: So help them develop and execute a plan to maximize
- 40:19Speaker 5: engagement with these various stakeholders. So first they need to
- 40:23Speaker 5: idate on a roadmap what they want to present and
- 40:26Speaker 5: when taking into account that information needs and gaps that
- 40:31Speaker 5: they need to fill, and then it is aligned with
- 40:34Speaker 5: where their product is at in its life cycle, because
- 40:36Speaker 5: obviously what they're going to present in pre approval is
- 40:39Speaker 5: very different from what they're going to present two three
- 40:42Speaker 5: years post approval and taking into account healthcare decision maker
- 40:46Speaker 5: review timelines. And then based on that strategy, they should
- 40:50Speaker 5: execute that tactic by providing and presenting the materials accordingly.
- 40:56Speaker 5: Obviously they should be monitoring activity metrics and monitoring fees back.
- 41:00Speaker 6: Along the way on the value of the content that.
- 41:03Speaker 5: They're providing and where there are additional information needs so
- 41:06Speaker 5: that they can continue to refine that information sharing strategies.
- 41:12Speaker 5: So that's really the third stage. And then finally, and
- 41:15Speaker 5: I think I can underestimate the importance of this, but
- 41:18Speaker 5: they really do need to monitor key performance indicators of
- 41:23Speaker 5: success with these engagements, such as what impact did this
- 41:26Speaker 5: have on product perceptions and of course ultimately market access
- 41:31Speaker 5: and trickling all the way down to patient access to
- 41:34Speaker 5: the product.
- 41:35Speaker 8: Absolutely, Laurie, I agree, and I think you know, we
- 41:38Speaker 8: can really measure how this has gone in formulay decisions, right,
- 41:42Speaker 8: so we know that our clients that have these really
- 41:45Speaker 8: intentional processes and intentional approaches, they have demonstrated success.
- 41:49Speaker 4: They have increased decision.
- 41:51Speaker 8: Maker engagement with their products, they have more positive ratings
- 41:55Speaker 8: of their materials when decision makers access through the platform,
- 41:59Speaker 8: and they also have a larger share of product activity
- 42:01Speaker 8: compared to others who are in the same market basket. So,
- 42:05Speaker 8: you know, I think that's something that can be applied
- 42:07Speaker 8: to other types of digital engagement, but it's definitely this
- 42:11Speaker 8: approach in particular is something that we can measure on
- 42:14Speaker 8: formula decisions and really see the success and you know,
- 42:18Speaker 8: ultimately these factors lead to the same goal, which is
- 42:21Speaker 8: what we all have and again that's to improve the
- 42:24Speaker 8: lives of patients, and we in particular do that by
- 42:27Speaker 8: helping improve access to safe and effective therapies in a
- 42:30Speaker 8: timely manner.
- 42:34Speaker 3: So in closing any thoughts, any thoughts to you know
- 42:37Speaker 3: what what twenty twenty five or the future brings, you know.
- 42:42Speaker 8: I think this is I think of this as like
- 42:45Speaker 8: the start to an important discussion, right and I think, ultimately, Sheila,
- 42:49Speaker 8: what I want our listeners to remember is that digital
- 42:52Speaker 8: engagement is really important and it certainly is the way
- 42:54Speaker 8: of the future. But the second big point is you
- 42:57Speaker 8: cannot lose the human touch. And we hear that over
- 43:01Speaker 8: and over again, and I think a lot of people
- 43:03Speaker 8: hope that digital pen can take over, but it really can't.
- 43:07Speaker 8: We still need to have a human involved, whether it's
- 43:09Speaker 8: with AI tools, whether it's with live meetings with our
- 43:13Speaker 8: decision makers.
- 43:15Speaker 4: Humans are still important.
- 43:17Speaker 6: That's a really good point, Bridget.
- 43:18Speaker 5: Because when I think back to when we launched in
- 43:21Speaker 5: twenty ten and where we're at today, we've come so
- 43:24Speaker 5: far and I know there's so much more to do.
- 43:28Speaker 5: But we're always very cognizant of it does not replace
- 43:32Speaker 5: that live interaction that you need and want with your
- 43:37Speaker 5: customer stakeholders, and there is certain information that you absolutely
- 43:42Speaker 5: want to deliver in a live environment. I think of
- 43:44Speaker 5: some of those models, whether it's cost effectiveness models, budget
- 43:48Speaker 5: impact models, you want to deliver those live to present
- 43:53Speaker 5: a partnership with your customer stakeholders and to walk them
- 43:57Speaker 5: through that process. So I don't think digital replace this
- 44:00Speaker 5: is live, but it is certainly a wonderful compliment to
- 44:04Speaker 5: ensure that you're reaching everyone where they want to be.
- 44:09Speaker 3: And that's a perfect way to end our podcast. Thank
- 44:12Speaker 3: you so much, Bridget Laurie for chatting with me and
- 44:14Speaker 3: sharing this valuable information. As a reminder, n SP corporate
- 44:18Speaker 3: members are invited to be my guest on one complimentary
- 44:20Speaker 3: podcast per year. For more information about this or other
- 44:23Speaker 3: n e SP membership benefits and events, please feel free
- 44:26Speaker 3: to reach out to membership at na.
- 44:28Speaker 4: SP n E T dot org.
- 44:31Speaker 3: Visit our website at www dot n A s P
- 44:35Speaker 3: n E T dot org. Until next time, have a
- 44:38Speaker 3: great day.